PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM on May 20, 2026. This notification details BlackRock, Inc.'s holdings in Qiagen N.V., including both real and potential capital interests and voting rights through various indirect ownerships. The distribution shows BlackRock's significant stake, with a total capital interest of 11.52% and voting rights of 12.89%.
Qiagen N.V. stock (NL0012169213): Diagnostics group updates investors after solid Q1 2026
Qiagen N.V. has reiterated its full-year outlook after reporting solid first-quarter 2026 results, maintaining its focus for investors on molecular testing and life-science tools demand. The company's business model relies on recurring sales of consumables for its installed instruments, with key revenue drivers including sample preparation, PCR, and next-generation sequencing solutions. Qiagen, listed on both the Frankfurt Stock Exchange and NYSE, targets clinical diagnostics labs and research institutions globally, including a significant presence in the US market.
Qiagen N.V. Stock 12‑Month Price Target Cut to $42.04, Implies 20% Upside
Analysts have lowered the average 12-month price target for Qiagen N.V. stock from $43.12 to $42.04, with forecasts ranging from $36 to $49 per share. This new target suggests a potential upside of approximately 20% from its May 21 closing price. Despite the target cut, the consensus rating from 21 analysts remains "Buy," with 8 Buys and 13 Holds.
QIAGEN Discloses Million-Dollar Insider Share Purchase by Supervisory Board Member Trust
QIAGEN N.V. (QGEN) disclosed a significant open-market purchase of its common shares by The Stephen H. Rusckowski Living Trust, associated with a supervisory board member. The trust bought approximately $1.01 million worth of QIAGEN stock on the NYSE, indicating strong insider confidence. The transaction, executed on May 19, 2026, involved shares priced at $34.5213 each.
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR
This article announces a manager's transaction at QIAGEN N.V. The Stephen H. Rusckowski Living Trust, associated with a member of the administrative or supervisory body, purchased QIAGEN N.V. shares on the open market. The transaction involved 1,006,295.895 USD worth of shares at a price of 34.5213 USD per share on May 19, 2026.
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
QIAGEN has launched QIA Agent, an AI-powered digital assistant designed to streamline research workflows by providing scientific guidance, product information, and operational support through a conversational interface. This new platform aims to simplify experiment planning, product discovery, and access to technical information for researchers. It integrates with existing QIAGEN digital services and offers personalized experiences for logged-in users, ultimately enhancing laboratory efficiency.
Qiagen launches AI assistant for laboratory research
QIAGEN (NYSE:QGEN) has launched QIA Agent, an AI-powered digital assistant designed to streamline laboratory research by helping scientists plan experiments, identify products, and access technical information. The platform offers a conversational interface linking product data, protocols, and support resources, and integrates with existing QIAGEN tools. This launch comes amidst recent news of a collaboration with NVIDIA for bioinformatics, a lowered financial outlook for 2026 due to reduced demand, and adjusted analyst ratings.
New QIAGEN AI lab assistant is designed to speed experiment planning
QIAGEN N.V. (NYSE: QGEN) has launched QIA Agent, an AI-powered digital assistant for researchers. This tool aims to simplify experiment planning, product identification, and access to technical information through a single conversational interface. It integrates with QIAGEN's existing digital services, offering personalized experiences for logged-in users and supporting decision-making across Sample to Insight workflows.
Qiagen (QGEN) Securities Fraud Investigation - Levi & Korsinsky
Levi & Korsinsky has launched a securities fraud investigation into Qiagen N.V. (NASDAQ: QGEN) after the company slashed its FY 2026 sales-growth guidance, causing its stock to drop over 10%. The investigation focuses on whether Qiagen misled investors by failing to disclose deteriorating demand for its QuantiFERON TB test prior to the guidance cut. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky to learn about their legal rights.
Qiagen (QGEN) Securities Fraud Investigation - Levi & Korsinsky
Levi & Korsinsky, LLP launched a securities fraud investigation into Qiagen N.V. (NASDAQ: QGEN) after the company slashed its full-year 2026 sales-growth guidance, causing a significant drop in its stock price. The reduction was attributed to a decline in QuantiFERON TB test volumes, which contradicted earlier positive forecasts. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky to discuss their legal options.
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
Kirby McInerney LLP is investigating potential federal securities law violations by Qiagen N.V. (NYSE:QGEN) and its senior management. This investigation follows a significant drop in Qiagen's share price after the company announced preliminary first-quarter 2026 results, which showed a decline in net sales and an unexpected decrease in QuantiFERON product sales, contradicting earlier growth projections. Investors who purchased Qiagen securities are encouraged to contact the law firm to discuss their rights.
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
QIAGEN announced a collaboration with NVIDIA to integrate NVIDIA's accelerated computing and BioNeMo platform with QIAGEN Digital Insights' bioinformatics business. This initiative aims to enhance AI's role in drug discovery by using graph-based AI to better understand disease biology, identify therapeutic targets, and uncover biomarkers. The collaboration will support various stages of drug discovery, with initial pilot programs available to select pharmaceutical and biotechnology partners.
Qiagen N.V. stock (NL0012169213): earnings outlook and molecular diagnostics focus
Qiagen N.V. is once again drawing investor attention after its latest quarterly results and updated outlook, emphasizing its focus on molecular diagnostics and sample preparation. The company's business model relies on recurring revenue from consumables and higher-ticket instrument sales, with a significant portfolio targeting infectious disease diagnostics, oncology, and genetic analysis. While Qiagen has a strong position in the life science tools sector, its performance is influenced by regulatory developments, reimbursement dynamics, and the adoption pace of its diagnostic and research workflows.
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $36
Stifel has reiterated its Hold rating on Qiagen NV (QGEN.US) and maintained its price target at $36. This indicates the firm's continued neutral outlook on the company's stock performance.
Qiagen N.V. stock (NL0012169213): diagnostics specialist updates investors after Q1 results
Qiagen N.V. has reported its Q1 2026 results, reiterating its outlook and highlighting ongoing demand for molecular testing and life sciences products. The company focuses on sample and assay technologies, serving both clinical diagnostics and research markets with a business model that combines recurring consumables revenue with sales of automation platforms. US investors have direct access to Qiagen's shares on the NYSE, providing exposure to a European-based diagnostics company deeply involved in the American healthcare and research sectors.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released an announcement regarding voting rights, as informed by the Netherlands Authority For the Financial Markets (AFM). The notification, dated May 14, 2026, details changes in share and voting rights distribution for Bank of America Corporation concerning QIAGEN N.V. shares, including real and potential holdings through various entities.
Qiagen N.V. (QGEN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Qiagen N.V. (QGEN) following discrepancies in growth projections for its QuantiFERON product. The investigation stems from Qiagen's revised guidance on April 28, 2026, which contradicted earlier optimistic forecasts for 2026 growth, leading to a drop in the company's stock price. The firm is encouraging shareholders to contact them to learn more about the investigation and potentially assist in a class action lawsuit.
QGEN Maintained by Stifel -- Price Target Lowered to $36
Stifel analyst Daniel Arias has maintained a "Hold" rating on Qiagen (QGEN) but lowered the price target from $50 to $36. Despite the lowered target, GuruFocus's GF Value™ suggests QGEN is 37.3% undervalued at its current price of $32.98, with a solid GF Score™ of 70, primarily driven by strong profitability. Investors are advised to consider broader market conditions and the company's financial performance before making investment decisions.
Qiagen NV (QGEN) PT Lowered to $36 at Stifel on 'Lower Growth Outlook'
Stifel analyst Daniel Arias has lowered the price target for Qiagen NV (NYSE: QGEN) to $36.00 from $50.00, citing a "Lower Growth Outlook." The analyst maintained a rating, though the specific rating is not mentioned in the provided snippet. The article notes that this is premium content, requiring a subscription to read further details.
Qiagen N.V. stock (NL0012169213): earnings momentum and diagnostics demand keep investors watching
Qiagen N.V. has reported its latest quarterly results and affirmed its outlook, maintaining investor focus on the diagnostics and life-science tools provider amidst fluctuating healthcare markets. The company's business model leverages recurring consumable sales and an extensive installed base of instruments, positioning it to benefit from long-term trends in precision medicine and expanded genomic testing. US investors have direct access to Qiagen through its Nasdaq listing, with the company's performance influenced by US healthcare spending and R&D budgets despite its German headquarters.
Qiagen N.V. stock (NL0012169213): Q1 2026 earnings and outlook keep diagnostics specialist in focus
Qiagen N.V. reported its Q1 2026 earnings, showing stable earnings per share (EPS) in line with analyst expectations, but revenues were slightly below consensus. The diagnostics specialist's stock is trading well below its 52-week high, making it a focus for US investors. The company's core business model, driven by recurring sales of reagents and test kits, positions it in a competitive market influenced by precision medicine and genetic testing trends.
Qiagen NV (QGEN) price target decreased by 13.91% to 46.28
The article reports that the price target for Qiagen NV (QGEN) has been decreased by 13.91% to $46.28. No further details are provided in the current content.
QIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is
Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against Qiagen N.V. (NYSE: QGEN) on behalf of its stockholders. The investigation stems from a significant drop in Qiagen's stock price after the company announced preliminary financial results for the first quarter of 2026, which showed a decline in net sales and QuantiFERON product sales, contradicting earlier growth expectations. The firm encourages investors who suffered losses to contact them to discuss their legal options.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGEN
Pomerantz LLP is investigating potential securities fraud claims against Qiagen N.V. (NYSE: QGEN) on behalf of its investors. This investigation follows a significant drop in Qiagen's stock price after the company announced preliminary first-quarter 2026 results, revealing a decline in net sales and QuantiFERON product sales. Investors who suffered losses are encouraged to contact the law firm.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Qiagen N.V. (QGEN) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Qiagen N.V. (QGEN) following discrepancies in its growth projections for QuantiFERON. The firm is encouraging investors who purchased Qiagen securities and are aware of relevant facts or wish to assist in the investigation to contact them. The investigation stems from a significant change in guidance provided by Qiagen regarding its anticipated QuantiFERON sales growth in 2026.
Levi & Korsinsky Announces Investigation of Securities Claims Against Qiagen N.V. (QGEN)
Levi & Korsinsky, LLP has announced an investigation into potential securities claims against Qiagen N.V. (QGEN) after the company significantly cut its FY 2026 sales-growth and adjusted diluted EPS guidance. The investigation focuses on CEO Thierry Bernard and CFO Roland Sackers, who allegedly made optimistic public statements and signed SEC filings shortly before the guidance was slashed, potentially misleading investors. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky to discuss their legal rights.
Bank of America Discloses 3.11% Voting Stake in Qiagen
Bank of America and its affiliates have disclosed a combined 3.11% capital and voting interest in Qiagen, held indirectly through various entities like BofA Securities and Merrill Lynch. This significant institutional stake, revealed via a Dutch Authority for the Financial Markets notification, suggests continued strong U.S. institutional interest in Qiagen's equity. The disclosure does not signal an operational change but could impact the company's liquidity, governance, and market perception.
Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement according to Article 40, Section 1 of the WpHG, following a notification from the AFM on May 09, 2026. The notification details transactions on May 06, 2026, by Bank of America Corporation, concerning QIAGEN N.V. shares, outlining both real and potential voting rights and capital interests held indirectly through various Bank of America entities.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, following a notification from the Netherlands Authority For the Financial Markets (AFM) on May 9, 2026. The notification details transactions by Bank of America Corporation on May 6, 2026, outlining the distribution of shares and voting rights, totaling a 2.99% capital interest and voting rights for Bank of America and its indirectly controlled entities. QIAGEN N.V. states it is not responsible for the accuracy of this notification, which is available on the AFM website.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released information regarding a notification from the AFM (the Netherlands Authority For the Financial Markets) concerning voting rights. Bank of America Corporation is the person obliged to notify, related to transactions on May 8, 2026. The notification details the distribution of ordinary shares and swaps, showing Bank of America's capital interest and voting rights at 3.11% in QIAGEN N.V.
Qiagen N.V. stock (NL0012169213): Q1 earnings hit estimates, dividend declared
Qiagen N.V. reported Q1 2026 EPS of $0.54, meeting analyst expectations, and declared a $0.35 per share dividend. Despite a 28.9% year-to-date share price decline, the company maintains its position in molecular diagnostics and life sciences, driven by recurring revenue from consumables and strong performance in Genomics and Nucleic Acid Purification. US investors are interested in Qiagen's Nasdaq listing and its role in supporting drug development and clinical trials.
Qiagen NV (QGEN) price target decreased by 13.91% to 46.28
The article reports that the price target for Qiagen NV (QGEN) has been reduced by 13.91%, setting the new target at $46.28. This information indicates a revised outlook on the stock's future value by analysts or market observers. Further details would be needed to understand the reasons behind this significant price target adjustment.
Does Qiagen's (QGEN) Bigger Dividend and Governance Shift Signal a New Capital Allocation Playbook?
QIAGEN N.V. has proposed a 40% increase in its annual cash dividend to US$0.35 per share and announced governance changes, including appointing a co-founder as Honorary Chairman. This move suggests a focus on pairing governance refreshment with a clearer capital return framework. While these changes don't alter operational risks, they aim to enhance the investment narrative around cash generation and growth, with the QuantiFERON latent TB franchise expansion being a key operational catalyst.
Does Qiagen's (QGEN) Bigger Dividend and Governance Shift Signal a New Capital Allocation Playbook?
QIAGEN N.V. (QGEN) has proposed a 40% increase in its annual cash dividend and announced significant governance changes, including appointing a co-founder as Honorary Chairman, signaling a refreshed capital return framework. While these changes highlight a commitment to shareholder returns, the core investment narrative for QIAGEN still hinges on its molecular diagnostics and testing platforms driving earnings amid competitive and macro headwinds. The article emphasizes that operational risks and catalysts, like the expansion of the QuantiFERON franchise, remain key factors for the company's growth story.
Free cash flow per share of QIAGEN NV – MIL:1QGEN
This article provides the free cash flow per share for QIAGEN NV (MIL:1QGEN) on Euronext Milan. It presents basic financial information, indicating the market was closed at the time of the report. The content shows relevant financial data points like period, value, and change metrics for the company.
QGEN Investor Alert: Levi & Korsinsky Investigates Qiagen (QGEN) for Potential Securities Fraud
Levi & Korsinsky, LLP is investigating Qiagen (QGEN) for potential securities fraud following a significant drop in its share price. The investigation focuses on Qiagen's revised sales-growth outlook and adjusted diluted EPS guidance, which allegedly lacked required GAAP reconciliations, potentially depriving institutional investors of material information. Additionally, a reclassification of $498.4 million in debt from long-term to current is under scrutiny.
QGEN Investor Alert: Levi & Korsinsky Investigates Qiagen (QGEN) for Potential Securities Fraud
Levi & Korsinsky is investigating Qiagen (QGEN) for potential securities fraud. This alert follows a 10% drop in Qiagen's stock after the company slashed its FY 2026 sales-growth outlook and cut adjusted diluted EPS guidance. The investigation focuses on the company's alleged failure to provide GAAP reconciliations for forward-looking non-GAAP financial measures and the reclassification of nearly $500 million in debt from long-term to current, which the firm believes may have misled investors.
Qiagen N.V. stock (NL0012169213): Recent 3.28% gain amid YTD decline
Qiagen N.V. shares recently experienced a 3.28% increase, closing at $33.70 on May 12, 2026, despite a significant year-to-date decline of 28.9%. The company, a key player in the DNA analysis sector, stands to benefit from strong demand in life sciences tools and bioinformatics. US investors track its NYSE performance to gauge biotech sector trends and the company's strong positioning in high-growth areas.
QIAGEN Board Member Makes $2 Million Open-Market Share Purchase
Mark Stevenson, a board member of QIAGEN N.V. (QGEN), recently purchased common shares worth approximately $2.03 million on the open market at $33.79 per share. This significant transaction, executed on May 12, 2026, signals potential insider confidence in the company. Currently, analyst ratings for QGEN stock are a "Hold" with a $40.00 price target.
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR
QIAGEN N.V. announced that Mark Stevenson, a member of the administrative or supervisory body, conducted an open market purchase of common shares. The transaction involved 2,027,502.00 USD worth of shares at a price of 33.7917 USD per share, taking place on May 12, 2026. This notification was made in accordance with article 19 MAR regarding managers' transactions.
QIAGEN N.V. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Kirby McInerney LLP has initiated an investigation into potential securities fraud against Qiagen N.V. (NYSE:QGEN). This follows a significant drop in Qiagen's stock price after the company announced preliminary first-quarter 2026 results, revealing a decline in net sales and a 5% drop in its QuantiFERON product sales, contradicting earlier growth projections. The firm is inviting investors who purchased Qiagen securities to contact them regarding their rights.
Qiagen N.V. Announces Metin Colpan Decides Not to Stand for Re-Election of Supervisory Board
Qiagen N.V. announced that co-founder Dr. Metin Colpan will not seek re-election to the Supervisory Board at the upcoming Annual General Meeting but will be appointed Honorary Chairman. Dr. Colpan played a pivotal role in establishing Qiagen's scientific foundation and strategic direction, serving as CEO from 1985 to 2003 and continuing to contribute as a Supervisory Board member, including Chair of the Science & Technology Committee since 2014. His pioneering work in nucleic acid separation and purification significantly advanced molecular biology and clinical diagnostics.
QIAGEN To Appoint Dr. Metin Colpan As Honorary Chairman Of The Supervisory Board, Continue Governance Renewal And Propose Increased Returns At 2026 Annual General Meeting >QGEN
QIAGEN announced plans to appoint co-founder Dr. Metin Colpan as Honorary Chairman of the Supervisory Board. The company is actively pursuing governance renewal through continued shareholder engagement and proposes to increase returns to shareholders at its 2026 Annual General Meeting. This strategic move aims to strengthen leadership and enhance shareholder value.
QIAGEN co-founder to become Honorary Chair as dividend rises 40%
QIAGEN announced proposals for its 2026 Annual General Meeting, including the appointment of co-founder Dr. Metin Colpan as Honorary Chairman and a 40% increase in the annual dividend to $0.35 per share. The company also plans additional share repurchase authorizations, including a new $200 million synthetic share repurchase, reflecting a commitment to increasing shareholder returns and continuing governance renewal. Robert McMahon is nominated for election to the Supervisory Board, further strengthening its profile in global healthcare and finance.
QIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General Meeting
QIAGEN will propose several key initiatives at its 2026 Annual General Meeting, including appointing co-founder Dr. Metin Colpan as Honorary Chairman of the Supervisory Board. The company also plans to continue its Supervisory Board renewal, nominate Robert McMahon for election, increase its annual cash dividend by 40% to $0.35 per share, and authorize additional share repurchases, including a new $200 million synthetic share repurchase. These steps aim to enhance corporate governance and deliver increased returns to shareholders.
Qiagen N.V. stock (NL0012169213): Q1 earnings meet EPS but miss revenue
Qiagen N.V. reported its Q1 2026 earnings, with EPS matching analyst estimates at $0.54 but revenue of $492.32 million falling short of the $496.15 million forecast. The company also issued full-year guidance for EPS at $2.43 and revenue at $2.1 billion, both below consensus expectations. Despite the mixed results, Qiagen maintains a strong position in the molecular diagnostics market, relying on its key revenue drivers in sample technologies, assays, and bioinformatics, with a significant presence in the US market.
Qiagen N.V. (QGEN) Discusses Strategic Priorities and Latest Developments for QuantiFERON and Latent Tuberculosis Testing - Slideshow (NYSE:QGEN)
Qiagen N.V. (QGEN) released a slideshow discussing its strategic priorities and recent developments for its QuantiFERON product and latent tuberculosis testing. The company's Q1 2026 earnings showed an EPS of $0.54, meeting expectations, but revenue of $492.32M missed estimates by $6.88M, despite a 1.83% year-over-year increase.
PTA-CMS: QIAGEN N.V.: Release of a capital market information
QIAGEN N.V. announced the filing of its Form 6-K Report of Foreign Private Issuer for the quarterly period ended March 31, 2026, with the United States Securities and Exchange Commission (SEC). The document is now available on the company's website. This release provides essential financial information to the capital markets.
QIAGEN NV : Gets a Neutral rating from Barclays
Barclays's analyst Luke Sergott has maintained a "Neutral" rating for QIAGEN NV. This decision was published on May 8, 2026, at 3:27 AM EDT. The biotechnology and medical research company, listed under the symbol QGEN, received this unchanged recommendation following recent financial news.
QIAGEN Reports Full Results for Q1 2026
QIAGEN N.V. reported its full results for the first quarter of 2026, aligning with preliminary announcements, showcasing strong profitability despite mixed sales trends. Net sales increased 2% to $492 million on a reported basis, though decreased 1% at constant exchange rates, while adjusted diluted EPS was $0.54 CER. The company reconfirmed its full-year 2026 outlook, expecting net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER, acknowledging headwinds from lower QuantiFERON sales due to reduced immigration testing demand and cautious U.S. Life Sciences customer demand.
